SavedAdd your journal

Journals / Gülhane Tıp Dergisi / 2021 / Cilt: 63 - Sayı: 4

The relationship between HMGB1 and immune infiltration serves as a treatment target molecule in different cancer tissues: May be used therapeutic target for possible SARS- CoV-2 infection

Rahşan ILIKCI
Dilara Fatma Akın BALI
Pages
246–253
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: High expression profile of HMGB1 was determined in 8 different cancer tissues (colon adenocarcinoma, diffuse large B-cell lymphoma, glioblastoma multiforme, brain lower grade glioma, pancreatic adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma and thymoma) when compared with the healthy tissues (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: To illustrate which tumor cells may express high-mobility group box 1 (HMGB1), which is also Coronavirus disease-2019 (COVID-19) target molecule as a treatment option for possible severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) infection.
📊
Key Findings & Data:Methods: We investigated m-RNA expression patterns of HMGB1 in 33 different cancer tissues.
💡
Conclusion & Impact:Results: High expression profile of HMGB1 was determined in 8 different cancer tissues (colon adenocarcinoma, diffuse large B-cell lymphoma, glioblastoma multiforme, brain lower grade glioma, pancreatic adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma and thymoma) when compared with the healthy tissues (p
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Aims: To illustrate which tumor cells may express high-mobility group box 1 (HMGB1), which is also Coronavirus disease-2019 (COVID-19) target molecule as a treatment option for possible severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) infection. Methods: We investigated m-RNA expression patterns of HMGB1 in 33 different cancer tissues. HMGB1 m-RNA expression profiles were compared with the Gene Expression Profiling Interactive Analysis database. Comparisons of promoter methylation levels with the UALCAN database were also performed. Finally, the correlation between HMGB1 and immune cells was investigated by using TIMER tool. Results: High expression profile of HMGB1 was determined in 8 different cancer tissues (colon adenocarcinoma, diffuse large B-cell lymphoma, glioblastoma multiforme, brain lower grade glioma, pancreatic adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma and thymoma) when compared with the healthy tissues (p

🔖

Cite This Article

ILIKCI, R., BALI, D. F. A. (2022). The relationship between HMGB1 and immune infiltration serves as a treatment target molecule in different cancer tissues: May be used therapeutic target for possible SARS- CoV-2 infection. Gülhane Tıp Dergisi, Cilt: 63 - Sayı: 4, 246–253. https://ajindex.com/articles/526780

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32:1267-1284
  2. Hiraku Y, Guo F, Ma N, et al. Multi-walled carbon nanotube induces nitrative DNA damage in human lung epithelial cells via HMGB1-RAGE interaction and Toll-like receptor 9 activation. Part Fibre Toxicol. 2016;13:16
  3. Ong SP, Lee LM, Leong YF, Ng ML, Chu JJ. Dengue virus infection mediates HMGB1 release from monocytes involving PCAF acetylase complex and induces vascular leakage in endothelial cells. PLoS One. 2012;7:e41932
  4. Wang H, Ward MF, Fan XG, Sama AE, Li W. Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol. 2006;19:3-9
  5. Kempaiah KR, Kurosky A, Hosakote YM. Effects of HMGB1 gene silencing on respiratory syncytial virus-induced inflammatory response. J Immunol. 2018;(Suppl)200:166
  6. Roh JS, Sohn DH. Damage-Associated Molecular Patterns in Inflammatory Diseases. Immune Netw. 2018;18:e27
  7. Kany S, Vollrath JT, Relja B. Cytokines in Inflammatory Disease. Int J Mol Sci. 2019;20:6008
  8. Kang R, Chen R, Zhang Q, et al. HMGB1 in health and disease. Mol Aspects Med. 2014;40:1-116
  9. Nishibori M. [HMGB1 as a representative DAMP and anti-HMGB1 antibody therapy]. Nihon Yakurigaku Zasshi. 2018;151:4-8
  10. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020;92:418-423
  11. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020;55:105951
  12. Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol. 2020;215:108448
  13. Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020;50:620-632
  14. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98-W102
  15. Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017;19:649-658
  16. Li T, Fan J, Wang B, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017;77:e108-e110
  17. Wu T, Zhang W, Yang G, et al. HMGB1 overexpression as a prognostic factor for surviv